10-12 September 2018 //  Lancaster Royal Hotel, London



Oxford BioMedica has 20 years of experience in the field of gene and cell therapy and we were the first organisation to treat humans in vivo lentiviral based vectors.  Today, we have built our LentiVector® platform of exclusive cutting-edge technologies and capabilities with which we design, develop and produce gene and cell-based medicines for ourselves and for our partners. 

We already have product-related partnerships with Novartis, Immune Design, Orchard Therapeutics, licensed products and technology rights to Sanofi and GSK, and a R&D collaboration with Green Cross LabCell.

And we have our own proprietary pipeline of gene and cell therapy products addressing neurodegenerative and ocular diseases and a range of cancers, for which there are either no treatments or where therapy remains inadequate.

2017 Speakers

"It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance."

Bertrand Alexandre, Director, Marketing Europe, Celyad